Parul Desai, MD
Cardiovascular Disease · Austin, TXNPI 1922009976
Payments from drug & device makers
Across 16 payments — averaging $152.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Abiomed$458
- Welch Allyn$186
- Medtronic$129
- Abbott$114
- Kiniksa Pharmaceuticals International, PLC$111
- plus $215 from 4 others
What the payments were for
- Travel & lodging$1,20449%
- Food & beverage$1,05643%
- Other$1868%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 4 | $1,232 |
| Abiomed | 4 | $458 |
| Welch Allyn | 1 | $186 |
| Medtronic | 1 | $129 |
| Abbott | 1 | $114 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Boston Scientific | 1 | $53 |
| Heartflow, Inc. | 1 | $50 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$1,204
- Impella$381
- SPOT Vision Screener$186
- COREVALVE EVOLUT R$129
- Ultreon$114
- ARCALYST$111
How this compares
$2,445 in reported general payments places this provider in the 35th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 118 | $151,488 |
| EntrestoSacubitril/Valsartan | 63 | $75,529 |
| XareltoRivaroxaban | 36 | $40,428 |
| Repatha SureclickEvolocumab | 35 | $21,885 |
| Praluent PenAlirocumab | 33 | $15,640 |
| Repatha SyringeEvolocumab | 15 | $8,216 |
| Metoprolol Succinate | 298 | $4,991 |
| Flecainide Acetate | 52 | $2,574 |
| Losartan Potassium | 108 | $1,513 |
| Diltiazem 12hr ErDiltiazem Hcl | 11 | $1,372 |
| Lisinopril | 109 | $1,224 |
| Atorvastatin Calcium | 115 | $1,216 |
| Potassium Chloride | 43 | $1,043 |
| Amlodipine Besylate | 112 | $955 |
| Valsartan | 38 | $935 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Austin
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.